0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Carfilzomib in combination with either lenalidomide and dexamethasone or dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XX
L01XX Other antineoplastic agents
EMA approval status :
Approved
EMA approval date :
2015-11-19
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No